Universal Ibogaine Third Quarter 2024 Earnings: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2023)

Universal Ibogaine (CVE:IBO) Third Quarter 2024 Results

Key Financial Results

• Revenue: CA$536.7k (up 25% from 3Q 2023).

• Net loss: CA$862.4k (loss widened by 77% from 3Q 2023).

• CA$0.003 loss per share (in line with 3Q 2023).

earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Universal Ibogaine shares are down 33% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Universal Ibogaine (at least 3 which are concerning), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com